NP
Therapeutic Areas
Grifols Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Subcutaneous Immunoglobulin (SCIG) | Primary & Secondary Immunodeficiencies | Marketed |
| Alpha-1 Antitrypsin (AAT) | Alpha-1 Antitrypsin Deficiency (AATD) | Marketed |
| CHRONOS-PD Platform | Parkinson's Disease | Research |
| Next-Generation Coagulation Factors | Hemophilia A & B | Development |
Leadership Team at Grifols
TG
Thomas Glanzmann
Executive Chairman of the Board
RG
Raimon Grífols Roura
Co-CEO and Executive Vice-Chairman
VG
Victor Grífols Deu
Co-CEO
AA
Alfredo Arroyo
Chief Financial Officer (CFO)
JR
Jordi Ramentol
Chief Operating Officer (COO) - Biopharma Business Unit
SG
Sílvia Grífols
Board Member